Sequential anti-angiogenic therapy after immunotherapy for advanced bile duct cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests whether giving a drug that blocks blood vessel growth (anti-angiogenic therapy) after immunotherapy can help people with advanced bile duct, gallbladder, or cholangiocarcinoma that cannot be removed by surgery. The goal is to see if this sequence improves outcomes for patients who have not had prior treatment for advanced disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old
- You have advanced or metastatic biliary tract cancer (bile duct, gallbladder, or cholangiocarcinoma) that cannot be cured by surgery
- You have not received chemotherapy, immunotherapy, or anti-angiogenic therapy for advanced cancer (prior adjuvant therapy completed more than 6 months ago is okay)
- You have at least one tumor that can be measured on scans
- You are in good daily health (ECOG score 0 or 1) and expected to live at least 12 weeks
- Your blood counts, liver, and kidney function are within trial limits
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests combining immunotherapy (anti-PD-1/PD-L1 antibodies) with standard chemotherapy (gemcitabine and cisplatin) for people with advanced bile duct or gallbladder cancer that can't be removed by surgery. The goal is to see if this combination works better than chemo alone.
This trial tests a new combination of a drug that helps your immune system fight cancer, called sintilimab, along with chemotherapy. It is for people who have bile duct cancer or gallbladder cancer that has spread to other parts of the body and have not had treatment for this stage yet. The goal is to see if this combination helps shrink tumors or stops them from growing.
This trial tests a combination of two chemotherapy drugs and an immunotherapy drug, followed by targeted radiation, in people with bile duct or gallbladder cancer that cannot be removed with surgery. The goal is to see if this approach can shrink tumors and improve outcomes.
This trial tests a combination of a new immunotherapy drug (cadonilimab) with three chemotherapy drugs for advanced bile duct or gallbladder cancer that has already been treated with gemcitabine. The goal is to see if adding immunotherapy helps control the cancer better.
This trial tests a combination of chemotherapy, immunotherapy, and heat therapy (hyperthermia) with a special radiation technique for advanced bile duct or gallbladder cancer that hasn't been treated before. It aims to see if this combination can help shrink tumors and improve outcomes.
This trial tests a combination of radiation therapy (PULSAR), immunotherapy, and chemotherapy for advanced bile duct cancer. It aims to see if this approach can shrink tumors and improve survival.
Hear when a new Bile Duct Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.